

Resource Summary Report

Generated by NIF on Jul 28, 2026

FITC anti-human CD45

RRID:AB_2562050

Type: Antibody

Proper Citation

BioLegend Cat# 304038, RRID:AB_2562050

Antibody Information

URL: http://antibodyregistry.org/AB_2562050

Proper Citation: BioLegend Cat# 304038, RRID:AB_2562050

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone HI30

Antibody ID: AB_2562050

Vendor: BioLegend

Catalog Number: 304038

Alternative Catalog Numbers: 304054, 304006, 304005

Record Creation Time: 20250820T004543+0000

Record Last Update: 20250820T090812+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD45.

No alerts have been found for FITC anti-human CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Moret RA, et al. (2026) Modelling the Colorectal Cancer Immune Microenvironment Using Air-Liquid Interface Organoids for Personalised Therapeutic Evaluation. Cirugia espanola, 800285.

Malmström E, et al. (2025) Human proteome distribution atlas for tissue-specific plasma proteome dynamics. Cell, 188(10), 2810.

Yang W, et al. (2025) Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. Science advances, 11(29), eadw5228.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer cell, 43(2), 269.

Wang Y, et al. (2025) AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunity. Cell reports, 44(4), 115445.

Kulkarni AJ, et al. (2025) L-Phenylalanine is a metabolic checkpoint of human Th2 cells. Cell reports. Medicine, 6(12), 102466.

Bandyopadhyay S, et al. (2024) Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging. Cell, 187(12), 3120.

Yoshikawa T, et al. (2024) Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. Cell reports. Medicine, 5(5), 101526.

Wang Y, et al. (2024) Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. Cell reports. Medicine, 5(6), 101580.

Sureshchandra S, et al. (2023) Multimodal profiling of term human decidua demonstrates immune adaptations with pregravid obesity. Cell reports, 42(7), 112769.

Gutierrez E, et al. (2023) An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. Med (New York, N.Y.), 4(5), 326.

Liu X, et al. (2022) CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition. *Cancer cell*, 40(11), 1341.